Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Alone or With Atezolizumab in Solid Tumors
NCT03170960Phase 1Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of cabozantinib in urothelial carcinoma (UC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and 11 more (25 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum Tolerated Dose and/or Recommended Expansion Stage Dose at 21 days and Objective Response Rate at 59 months. Started Sep 2017; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
urothelial carcinoma (UC)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03170960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170960.